Comparative Pharmacology
Head-to-head clinical analysis: EVOMELA versus HEPZATO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOMELA versus HEPZATO.
EVOMELA vs HEPZATO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVOMELA (melphalan) is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
HEPZATO (melphalan) is a nitrogen mustard alkylating agent that crosslinks DNA strands, inhibiting DNA replication and transcription, leading to cell death.
140-200 mg/m² IV over 30 minutes for conditioning prior to ASCT; off-label: 16 mg/m² IV over 15-20 minutes every 4 weeks for MM.
Melphalan 3 mg/kg ideal body weight via hepatic artery infusion over 15-30 minutes followed by hemofiltration, administered once per treatment cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 75 minutes (range 40-120 minutes) in patients with normal renal function; prolonged to 180-300 minutes in renal impairment
The terminal elimination half-life of melphalan is approximately 1.5 hours following intravenous administration. This short half-life necessitates regional delivery (hepatic arterial infusion) to achieve high local concentrations with limited systemic exposure.
Primarily renal: approximately 10-30% of unchanged drug excreted in urine within 24 hours; extensive hepatic metabolism; fecal excretion accounts for <5%
HEPZATO (melphalan hydrochloride) for injection is renally eliminated; approximately 20-30% of the administered dose is excreted unchanged in the urine over 24 hours. The major metabolites are hydrolysis products, which are also excreted renally. Biliary/fecal elimination accounts for less than 10% of the dose.
Category C
Category C
Alkylating Agent
Alkylating Agent